CytoSorbents Q2 Loss Widens to $0.07/Share, Cash Drops to $5.9M Amid Going Concern
CTSO is trading near its 52-week low of $0.35 (14% above the low).
Summary
CytoSorbents reported Q2 2026 revenue flat at $9.6M, but net loss widened to $4.4M or $0.07 per share, driven by non-cash FX translation losses. Adjusted net loss improved 22% to $2.8M, and operating cash burn fell to $200K excluding restructuring, moving toward a targeted H2 2026 breakeven. However, unrestricted cash dwindled to $4.4M as of June 30, and the company reiterates a going concern warning. The 10-Q filed today confirms Nasdaq delisting risk persists. Four FDA pre-submission meetings are now scheduled for August 2026 to discuss the ticagrelor removal program, a critical regulatory catalyst. The upcoming August 13 shareholder vote on a reverse stock split is pivotal to maintaining the Nasdaq listing.
At the time of this announcement, CTSO was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.35 to $1.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.